RxDoctor Payments Data

Beth Stein, MD

Neuromuscular Medicine · Paterson, NJNPI 1710146865

Payments from drug & device makers

$87,454in general payments, 2019–2025

Across 133 payments — averaging $657.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$59K
  • UCB, Inc.$14K
  • Johnson & Johnson$7K
  • Amgen$4K
  • AstraZeneca$3K
  • Grifols USA, LLC$53
  • plus $164 from 10 others

What the payments were for

  • Consulting fees$37,64043%
  • Speaking & faculty fees$39,41445%
  • Travel & lodging$8,2249%
  • Food & beverage$2,0842%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$213,617
Medicare patients
434
Services billed
1,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5079$1,248,989
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5034$752,477
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc11$681,773
EvrysdiRisdiplam14$361,373
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$324,833
GammakedImmune Globul G/Gly/Iga Avg 4614$124,005
UbrelvyUbrogepant29$57,367
Pyridostigmine Bromide ErPyridostigmine Bromide26$15,675
KeppraLevetiracetam12$14,105
VimpatLacosamide12$13,154
Pyridostigmine Bromide117$9,159
Lacosamide60$7,385
Levetiracetam180$4,895
Gabapentin349$2,987
Pregabalin112$1,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$23$1,248,98979 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$20$752,47734 claims
Argenx US, Inc.Vyvgart Hytrulo$59,144$681,77311 claims
Genentech USA, Inc.Evrysdi$12$361,37314 claims
Grifols USA, LLCGamunex-C$53$324,83324 claims
AbbVieUbrelvy$17$57,36729 claims
UCB, Inc.Vimpat$14,495$13,15412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Paterson

Where these figures come from

Is this you, or does something look wrong? →